Technical Analysis for REPH - Recro Pharma, Inc.

Grade Last Price % Change Price Change
grade B 17.13 1.60% 0.27
REPH closed up 1.6 percent on Wednesday, November 13, 2019, on 1.54 times normal volume. The bulls were able to push the stock to a new 52-week high. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical REPH trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Calm After Storm Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Wide Bands Range Expansion 1.60%
Overbought Stochastic Strength 1.60%
New 52 Week Closing High Bullish -1.89%

Older signals for REPH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, is engaged in the development of various non-opioid therapeutics for the treatment of pain and related conditions in the United States. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Medicine Pain Chronic Pain Perception Stage Specialty Pharmaceutical Imidazoles Neuropathic Pain Purdue Pharma Sensory Systems
Is REPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.198
52 Week Low 5.53
Average Volume 240,624
200-Day Moving Average 10.187
50-Day Moving Average 12.8445
20-Day Moving Average 14.706
10-Day Moving Average 16.465
Average True Range 0.8642
ADX 55.36
+DI 40.3273
-DI 8.0989
Chandelier Exit (Long, 3 ATRs ) 15.6054
Chandelier Exit (Short, 3 ATRs ) 13.6526
Upper Bollinger Band 18.4258
Lower Bollinger Band 10.9862
Percent B (%b) 0.83
BandWidth 50.588875
MACD Line 1.3743
MACD Signal Line 1.1549
MACD Histogram 0.2193
Fundamentals Value
Market Cap 326.48 Million
Num Shares 19.1 Million
EPS -2.12
Price-to-Earnings (P/E) Ratio -8.08
Price-to-Sales 2.35
Price-to-Book 2.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.93
Resistance 3 (R3) 19.08 18.64 18.63
Resistance 2 (R2) 18.64 18.18 18.56 18.53
Resistance 1 (R1) 17.89 17.90 17.66 17.73 18.43
Pivot Point 17.44 17.44 17.33 17.36 17.44
Support 1 (S1) 16.69 16.99 16.47 16.53 15.83
Support 2 (S2) 16.24 16.70 16.17 15.73
Support 3 (S3) 15.49 16.24 15.63
Support 4 (S4) 15.33